GLP-1 receptor agonists (GLP-1 RA) medications can reduce the number of deaths, amputations and hospitalisations among patients with peripheral arterial disease (PAD) and type 2 diabetes, according to new, independent research published in the Journal of the American Heart Association ( JAHA )
Recommendations include: 150-300 minutes weekly moderate-intensity aerobic activity Resistance training 2-3 times weekly to maintain muscle mass Non-exercise activity thermogenesis (NEAT) optimization through increased daily movement Pharmacological Alternatives: Beyond GLP-1 receptor agonists, FDA-approved weight loss medications include: Phentermine-topiramate (Qsymia): Appetite suppressant combination Naltrexone-bupropion (Contrave): Affects reward pathways and appetite Orlistat (Xenical, Alli): Lipase inhibitor reducing fat absorption These alternatives have different mechanisms, adverse effect profiles, and efficacy (typically 5-10% weight loss), allowing individualized selection
The tolerable upper intake level set by the Institute of Medicine is 100 mg per day for adults, and the compounded dose is a small fraction of that
These may not fully reflect real-world outcomes in Greece and, given the BMI-only surrogate approach, may underestimate pathways not directly mediated through BMI